# Lactobacillus murinus Alleviates High Fructose‐Induced MASLD by Boosting Arginine Production

**Authors:** Xinglin Mo, Guilin Zhao, Lanlan Liu, Lan Zhen, Qing Huang, Yue Wang, Xiaopan Yang, Linfei Huang, Luming Wan, Congwen Wei, Ruzhou Zhao, Jie Hu, Yong Li, Jing Yuan, Chenke Ma, Feixiang Wu

PMC · DOI: 10.1002/fsn3.71502 · Food Science & Nutrition · 2026-02-17

## TL;DR

This study shows that Lactobacillus murinus and arginine can help treat liver disease caused by high fructose diets.

## Contribution

The study identifies Lactobacillus murinus and arginine as potential therapeutic agents for fructose-induced MASLD.

## Key findings

- Lactobacillus murinus supplementation reduces MASLD symptoms in mice.
- Arginine levels are linked to Lactobacillus murinus abundance and can alleviate MASLD.
- Direct arginine supplementation provides similar benefits as Lactobacillus murinus.

## Abstract

Over the past few years, the prevalence of high‐fructose diets has become a significant inducer of metabolic dysfunction‐associated steatotic liver disease (MASLD). The effects and pathological mechanisms of high dietary fructose on gut microbiota and its subsequent role in MASLD remain unclear. Here, we investigated the impact of fructose supplementation on MASLD progression in wild‐type C57BL/6 mice using both high‐fructose drinking water and a high‐fructose diet. Through 16S rDNA sequencing, we observed that long‐term fructose exposure significantly reduced the abundance of 
Lactobacillus murinus
 (
L. murinus
) in the intestines of mice. We aim to further elucidate the role and underlying mechanisms of 
L. murinus
 in high‐fructose‐induced MASLD. Logically, we supplemented 
L. murinus
 exogenously in the high‐fructose mouse model and found that 
L. murinus
 significantly alleviated fructose‐induced MASLD symptoms, characterized by reduced liver ballooning, inflammation, hepatic cholesterol, triglycerides, as well as decreased blood cholesterol, triglycerides, ALT and AST levels. To further investigate the mechanistic basis of 
L. murinus
‐mediated protection, we conducted serum and fecal metabolomic analyses. These studies identified arginine as the sole metabolite exhibiting marked reductions in both serum and intestinal compartments. Integrated multi‐omics analysis revealed a strong positive correlation between gut 
L. murinus
 abundance and arginine levels. ELISA demonstrated that exogenous administration of 
L. murinus
 effectively restored circulating arginine concentrations in high‐fructose‐fed mice. Importantly, direct arginine supplementation produced similar therapeutic benefits as 
L. murinus
. Specifically, it improved key features of MASLD, including reduced liver ballooning, less liver inflammation, lower buildup of cholesterol and triglycerides in the liver and blood, and decreased ALT/AST levels. These data revealed a novel mechanism underlying fructose‐induced MASLD by decreasing the abundance of gut 
L. murinus
, which disrupts arginine metabolism. 
L. murinus
 and arginine could serve as potential therapeutic strategies against fructose‐induced MASLD.

Long‐term high‐fructose diet significantly reduced the abundance of 
Lactobacillus murinus
 in the intestines of mice. 
Lactobacillus murinus
 was found to be significantly associated with arginine metabolism. Exogenous supplementation of 
Lactobacillus murinus
 alleviated fructose‐induced MASLD and restored serum arginine levels, and direct arginine supplementation exerted comparable therapeutic effects.

## Linked entities

- **Chemicals:** fructose (PubChem CID 5984), arginine (PubChem CID 232), cholesterol (PubChem CID 5997)
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), MASLD (MONDO:0013209)

## Full-text entities

- **Genes:** Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Nos1 (nitric oxide synthase 1, neuronal) [NCBI Gene 18125] {aka 2310005C01Rik, N-NOS, NC-NOS, NO, NOS, NOS-I}, Gck (glucokinase) [NCBI Gene 103988] {aka GLK, Gk, Gls006, HK4, HKIV, HXKP}, Khk (ketohexokinase) [NCBI Gene 16548], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Lpin1 (lipin 1) [NCBI Gene 14245] {aka Lipin1, fld}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), septic (MESH:D001170), liver damage (MESH:D056486), liver hypertrophy (MESH:D017093), DNL (MESH:D005862), bacterial infections (MESH:D001424), lobular (MESH:D018275), insulin resistance (MESH:D007333), cardiovascular diseases (MESH:D002318), colitis (MESH:D003092), immune disorders (MESH:D007154), abnormalities in hepatic lipid metabolism (MESH:D052439), endotoxemia (MESH:D019446), metabolic diseases (MESH:D008659), fat (MESH:D004620), arginine deficiency for NOS (MESH:C567192), Hepatic Steatosis (MESH:D005234), obesity (MESH:D009765), NAFLD (MESH:D065626), Tumor (MESH:D009369), HFrD (MESH:D000069578), gut dysbiosis (MESH:D064806), diabetes (MESH:D003920), chronic inflammation (MESH:D007249), Impaired Liver Function (MESH:D008107), metabolic deficiencies (MESH:D024821)
- **Chemicals:** Formalin (MESH:D005557), glucose (MESH:D005947), SCFAs (MESH:D005232), PBS (MESH:D007854), GA (MESH:D005985), acetate (MESH:D000085), DHAP (MESH:D004099), lipid (MESH:D008055), chloroform (MESH:D002725), polyamine (MESH:D011073), -fructose (MESH:D005632), fatty acids (MESH:D005227), Arg (MESH:D001120), butyrate (MESH:D002087), glycerol (MESH:D005990), A5006 (-), bile acids (MESH:D001647), H&amp;E (MESH:D006371), valeric acid (MESH:C038780), L-ornithine (MESH:D009952), cholesterol (MESH:D002784), NO (MESH:D009569), ethanol (MESH:D000431), trimethylamine (MESH:C023336), drinking water (MESH:D060766), acetyl-CoA (MESH:D000105), Oil Red O (MESH:C011049), water (MESH:D014867), monosaccharide (MESH:D009005), acetonitrile (MESH:C032159), TG (MESH:D014280), sodium pentobarbital (MESH:D010424), xylene (MESH:D014992), nitrogen (MESH:D009584), acid (MESH:D000143), paraffin (MESH:D010232), fat (MESH:D005223), pyruvate (MESH:D019289), OCT (MESH:C051883), 3-HB (MESH:D020155), methanol (MESH:D000432)
- **Species:** Limosilactobacillus reuteri (species) [taxon 1598], gut metagenome (species) [taxon 749906], Lactiplantibacillus plantarum (species) [taxon 1590], Limosilactobacillus fermentum (species) [taxon 1613], Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606], Microbiota (genus) [taxon 13613], Bifidobacterium (genus) [taxon 1678], Lactobacillus gasseri (species) [taxon 1596], Odoribacter (genus) [taxon 283168], Akkermansia muciniphila (species) [taxon 239935], Lactobacillus acidophilus (species) [taxon 1579], Saccharomyces boulardii [taxon 252598], Lacticaseibacillus rhamnosus (species) [taxon 47715], Mus musculus (house mouse, species) [taxon 10090], Ileibacterium valens (species) [taxon 1862668], Ligilactobacillus murinus (species) [taxon 1622]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12910522/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12910522/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12910522/full.md

---
Source: https://tomesphere.com/paper/PMC12910522